This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Razadyne - IR and ER

Johnson & Johnson

Drug Names(s): Reminyl, Galantamine HBr, Galantamine Prolonged-Release (PR)/Controlled-Release (CR), R113675

Description: Reminyl (Galantamine, Razadyne), a tertiary alkaloid, is a competitive and reversible inhibitor of the enzyme acetylcholinesterase, with less affinity for butyrylcholinesterase. Inhibition of cholinesterases, which break down acetylcholine, leads to increased levels of acetylcholine in the brain, helping to boost cognition in Alzheimer's disease, where acetylcholine containing nerves are reduced. Reminyl also modulates nicotinic receptors, which may enhance release of ACh and potentiate the response of nicotinic receptors to Ach, though this has not been shown to lead to clinically meaningful advantages.

Deal Structure: Razadyne was originally licensed from Synaptech, the patent holder. In a January 1996 codevelopment agreement, Johnson & Johnson licensed the worldwide rights for the drug from Shire Pharmaceuticals. In April 2004, Shire reacquired exclusive marketing rights in the UK and Ireland. Shire receives royalties on JNJ sales.

In April 2010, Takeda announced that it signed an agreement dated March 31, 2010 with JANSSEN PHARMACEUTICAL K.K. and Janssen Pharmaceutica N.V. regarding co-marketing in Japan of galantamine (R113675). Once approved in Japan, Takeda and Janssen Pharma will co-market galantamine under the same brand name. Under the agreement, Takeda receives rights to co-market galantamine in Japan, and will make an upfront contractual payment, as well as launch & annual sales milestone payments to Janssen Pharma and Janssen Pharmaceutica. In addition, Takeda will pay a fixed rate based on sales. Other contractual details were not disclosed.

Abbvie and Shire
In...See full deal structure in Biomedtracker

Partners: Shire Pharmaceuticals Group PLC Takeda Pharmaceutical Company Ltd


Razadyne - IR and ER News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug